Page last updated: 2024-12-11
ym 26734
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
YM 26734: inhibits group II phospholipase A2; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9853400 |
| CHEMBL ID | 444450 |
| MeSH ID | M0223763 |
Synonyms (30)
| Synonym |
|---|
| ym 26734 |
| bdbm50274336 |
| 1-{3-dodecanoyl-2,4,6-trihydroxy-5-[7-hydroxy-2-(4-hydroxy-phenyl)-chroman-4-yl]-phenyl}-dodecan-1-one |
| CHEMBL444450 , |
| ym-26734 |
| 144337-18-8 |
| d27z1v25bz , |
| 1-dodecanone, 1,1'-(5-(3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2h-1-benzopyran-4-yl)-2,4,6-trihydroxy-1,3-phenylene)bis- |
| 4-(3,5-didodecanoyl-2,4,6-trihydroxyphenyl)-7-hydroxy-2-(4-hydroxyphenyl)chroman |
| unii-d27z1v25bz |
| AKOS024457146 |
| 1,1'-[5-[3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2h-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis-1-dodecanone |
| 1,1'-(5-(3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2h-1-benzopyran-4-yl)-2,4,6-trihydroxy-1,3-phenylene)bis(1-dodecanone) |
| ym-26734, >=95% (hplc) |
| J-007943 |
| DTXSID20932293 |
| 1,1'-{2,4,6-trihydroxy-5-[7-hydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-yl]-1,3-phenylene}di(dodecan-1-one) |
| ym26734 |
| NCGC00387064-05 |
| Q27276004 |
| 1-dodecanone, 1,1'-[5-[3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2h-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis- |
| 1-[3-dodecanoyl-2,4,6-trihydroxy-5-[7-hydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]phenyl]dodecan-1-one |
| A899245 |
| 1,1'-(2,4,6-trihydroxy-5-(7-hydroxy-2-(4-hydroxyphenyl)chroman-4-yl)-1,3-phenylene)bis(dodecan-1-one) , |
| EX-A4737 |
| AS-80369 |
| CS-0029309 |
| HY-108609 |
| AC-36612 |
| F90262 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (8)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Group 10 secretory phospholipase A2 | Homo sapiens (human) | IC50 (µMol) | 0.9000 | 0.0410 | 0.1038 | 0.2000 | AID389109; AID389113 |
| Phospholipase A2, membrane associated | Oryctolagus cuniculus (rabbit) | IC50 (µMol) | 0.0850 | 0.0850 | 0.0850 | 0.0850 | AID389111 |
| Phospholipase A2, membrane associated | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.1200 | 0.1200 | 0.1200 | 0.1200 | AID389106 |
| Phospholipase A2, membrane associated | Homo sapiens (human) | IC50 (µMol) | 0.5400 | 0.0030 | 1.0811 | 8.0000 | AID389108; AID389112 |
| Phospholipase A2, membrane associated | Mus musculus (house mouse) | IC50 (µMol) | 0.0300 | 0.0300 | 0.0800 | 0.1500 | AID389107 |
| Phospholipase A2 group V | Homo sapiens (human) | IC50 (µMol) | 0.1100 | 0.1000 | 0.2256 | 0.5000 | AID389105 |
| Phospholipase A2 group V | Mus musculus (house mouse) | IC50 (µMol) | 0.5200 | 0.1700 | 0.5475 | 0.7500 | AID389104 |
| Group 10 secretory phospholipase A2 | Mus musculus (house mouse) | IC50 (µMol) | 1.6000 | 0.0750 | 0.3500 | 0.9000 | AID389110 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (52)
Molecular Functions (8)
Ceullar Components (15)
Bioassays (10)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID389109 | Inhibition of human sPLA2 group 10 | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Simplified YM-26734 inhibitors of secreted phospholipase A2 group IIA. |
| AID389107 | Inhibition of mouse sPLA2 group 2A | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Simplified YM-26734 inhibitors of secreted phospholipase A2 group IIA. |
| AID389105 | Inhibition of human sPLA2 group 5 | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Simplified YM-26734 inhibitors of secreted phospholipase A2 group IIA. |
| AID389113 | Inhibition of sPLA2 group 10 | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Simplified YM-26734 inhibitors of secreted phospholipase A2 group IIA. |
| AID389106 | Inhibition of rat sPLA2 group 2A | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Simplified YM-26734 inhibitors of secreted phospholipase A2 group IIA. |
| AID389110 | Inhibition of mouse sPLA2 group 10 | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Simplified YM-26734 inhibitors of secreted phospholipase A2 group IIA. |
| AID389112 | Inhibition of sPLA2 group 2A | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Simplified YM-26734 inhibitors of secreted phospholipase A2 group IIA. |
| AID389108 | Inhibition of human sPLA2 group 2A | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Simplified YM-26734 inhibitors of secreted phospholipase A2 group IIA. |
| AID389111 | Inhibition of rabbit sPLA2 group 2A | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Simplified YM-26734 inhibitors of secreted phospholipase A2 group IIA. |
| AID389104 | Inhibition of mouse sPLA2 group 5 | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Simplified YM-26734 inhibitors of secreted phospholipase A2 group IIA. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.58
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.58) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||